Neuland Laboratories Limited (NSE:NEULANDLAB) — Market Cap & Net Worth
Market Cap & Net Worth: Neuland Laboratories Limited (NEULANDLAB)
Neuland Laboratories Limited (NSE:NEULANDLAB) has a market capitalization of $2.08 Billion (Rs192.49 Billion) as of May 2, 2026. Listed on the NSE stock exchange, this India-based company holds position #6104 globally and #266 in its home market, demonstrating a -0.42% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Neuland Laboratories Limited's stock price Rs15003.00 by its total outstanding shares 12829889 (12.83 Million). Analyse Neuland Laboratories Limited operating cash flow efficiency to see how efficiently the company converts income to cash.
Neuland Laboratories Limited Market Cap History: 2015 to 2026
Neuland Laboratories Limited's market capitalization history from 2015 to 2026. Data shows growth from $108.45 Million to $2.08 Billion (32.37% CAGR).
Index Memberships
Neuland Laboratories Limited is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NIFTY MICROCAP 250
NIFTYMICROCAP250
|
$143.76 Billion | 1.45% | #10 of 250 |
|
NIFTY TOTAL MARKET
NIFTYTOTALMKT
|
$3.20 Trillion | 0.07% | #237 of 750 |
Weight: Neuland Laboratories Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Neuland Laboratories Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Neuland Laboratories Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.14x
Neuland Laboratories Limited's market cap is 0.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.81x
Neuland Laboratories Limited's market cap is 0.81 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $140.52 Million | $5.10 Billion | $273.25 Million | 0.03x | 0.51x |
| 2017 | $121.53 Million | $5.79 Billion | $468.65 Million | 0.02x | 0.26x |
| 2018 | $62.39 Million | $5.13 Billion | $120.63 Million | 0.01x | 0.52x |
| 2019 | $57.05 Million | $6.46 Billion | $164.42 Million | 0.01x | 0.35x |
| 2020 | $150.32 Million | $7.64 Billion | $162.10 Million | 0.02x | 0.93x |
| 2021 | $212.36 Million | $9.24 Billion | $806.31 Million | 0.02x | 0.26x |
| 2022 | $230.09 Million | $9.23 Billion | $638.22 Million | 0.02x | 0.36x |
| 2023 | $732.89 Million | $11.61 Billion | $1.64 Billion | 0.06x | 0.45x |
| 2024 | $1.90 Billion | $15.59 Billion | $3.00 Billion | 0.12x | 0.63x |
| 2025 | $2.11 Billion | $14.77 Billion | $2.60 Billion | 0.14x | 0.81x |
Competitor Companies of NEULANDLAB by Market Capitalization
Companies near Neuland Laboratories Limited in the global market cap rankings as of May 2, 2026.
Key companies related to Neuland Laboratories Limited by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Neuland Laboratories Limited Historical Marketcap From 2015 to 2026
Between 2015 and today, Neuland Laboratories Limited's market cap moved from $108.45 Million to $ 2.08 Billion, with a yearly change of 32.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rs2.08 Billion | -1.13% |
| 2025 | Rs2.11 Billion | +10.57% |
| 2024 | Rs1.90 Billion | +159.82% |
| 2023 | Rs732.89 Million | +218.53% |
| 2022 | Rs230.09 Million | +8.35% |
| 2021 | Rs212.36 Million | +41.28% |
| 2020 | Rs150.32 Million | +163.51% |
| 2019 | Rs57.05 Million | -8.57% |
| 2018 | Rs62.39 Million | -48.66% |
| 2017 | Rs121.53 Million | -13.51% |
| 2016 | Rs140.52 Million | +29.57% |
| 2015 | Rs108.45 Million | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Neuland Laboratories Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.08 Billion USD |
| MoneyControl | $2.08 Billion USD |
| MarketWatch | $2.08 Billion USD |
| marketcap.company | $2.08 Billion USD |
| Reuters | $2.08 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.